ESPResearch has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer. The research, from the group of Professor Sophia Karagiannis at King's College London, could help to better understand the responses of patients who receive this type of therapy.
Antibody treatments are a type of immunotherapy, which work by helping the body's immune system to recognize and kill cancer cells. Almost all antibodies currently used in cancer treatment are made from a type of antibody called IgG, however, IgGs have not been effective against ovarian cancer.
Researchers at King's are the first in the world to develop a treatment from a different type of antibody, called IgE. IgE has important roles in triggering the immune response during an allergic reaction or by stimulating immune cells to fight parasite infections. Unlike IgG antibodies, which activate immune cells circulating in the blood, IgE antibodies bind very tightly to immune cells found in tissues. The team has been working to harness these immune-boosting activities of IgE against solid cancers.
The team investigated an IgE antibody called MOv18, exploring its ability to activate immune cells from patients with ovarian cancer and its influence on the tumor’s environment.
The research showed that MOv18 IgE works in a unique way, by reversing the suppression of the immune system imposed by the tumor, through activation of different groups of immune cells against the cancer.
Know more: https://www.sciencedaily.com/releases/2025/04/250410130742.htm
